首页> 外文OA文献 >Differential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms
【2h】

Differential NOD/SCID mouse engraftment of peripheral blood CD34 + cells and JAK2V617F clones from patients with myeloproliferative neoplasms

机译:骨髓增生性肿瘤患者外周血CD34 +细胞和JaK2V617F克隆的差异NOD / sCID小鼠植入

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We evaluated the NOD/SCID engraftment of CD34 + cells from polycythemia vera (PV) and secondary polycythemia patients (SP) and the JAK2V617F clone before and after transplantation. Peripheral blood CD34 + cells were transplanted intra-femorally. In the injected BM, successful engraftment (>0.1%) occurred in 8/26 mice transplanted with CD34+ cells from 5/13 PV patients (median: 4.26%, range: 0.3-5.56%), in contrast to 0/14 mice from 9 SP patients (P=0.017). The engrafting PV cells were of multi-lineage. JAK2V617F/total JAK2 ratios decreased after transplantation (initial: 65.9% versus 6-week: 13.0%, P=0.001). Essential thrombocythemia (ET) BM cells also exhibited a similar decrease in JAK2V617F clone. The results suggested that events in addition to JAK2V617F are involved in the pathogenesis of PV and ET. © 2010 Elsevier Ltd.
机译:我们评估了真性红细胞增多症(PV)和继发性红细胞增多症患者(SP)的CD34 +细胞在移植前后的NOD / SCID植入以及JAK2V617F克隆。股骨内移植外周血CD34 +细胞。在注射的BM中,成功移植(> 0.1%)的是移植有来自5/13 PV患者的CD34 +细胞的8/26小鼠(中位数:4.26%,范围:0.3-5.56%),而来自0/14小鼠9名SP患者(P = 0.017)。移植的PV细胞具有多谱系。移植后JAK2V617F /总JAK2比率降低(初始:65.9%对6周:13.0%,P = 0.001)。原发性血小板增多症(ET)BM细胞在JAK2V617F克隆中也表现出相似的减少。结果表明,除了JAK2V617F之外,其他事件均与PV和ET的发病机制有关。 ©2010爱思唯尔有限公司。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号